Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
AIIMS Delhi Transfers India-Trained AI Mammography Technology to BPL for Clinical Development
AIIMS Delhi has transferred its AI-based mammography interpretation model to BPL Medical Technologies for further development and clinical validation, aiming to bring specialist-level breast cancer screening support to India's tier…
Centre Begins Talks on Trade-Margin Rationalisation for Medical Devices and Hospital Consumables
India's Centre has started stakeholder talks with the medical device industry and private hospitals on trade-margin rationalisation, after Maharashtra's FDA flagged markups up to 2,841% on hospital consumables like IV…
White House Reportedly Considers Direct Political Oversight of NIH Research Grants
Trump has reportedly directed OMB Director Russell Vought to draft an executive order creating a board, including NIH Director Jay Bhattacharya, with unanimous final authority over NIH grant funding, following…
AI Health Insurer Angle Health Raises $600 Million at $2.7 Billion Valuation
Angle Health, an AI-native health benefits platform for small businesses founded by ex-Palantir engineers, has raised $600 million led by Vitruvian Partners at a $2.7 billion valuation, more than doubling…
All 50 US States Join Trump’s New Medicaid International Drug-Pricing Model
All 50 states, DC, and Puerto Rico have applied to join the Trump administration's GENEROUS Medicaid drug-pricing model, which ties prices to what other developed nations pay, with projected savings…
FDA Approves Lilly’s Inluriyo Plus Verzenio Combination for ESR1-Mutated Advanced Breast Cancer
The FDA has approved Eli Lilly's Inluriyo (imlunestrant) plus Verzenio (abemaciclib) for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, doubling median progression-free survival to 11.1 months in the Phase 3 EMBER-3…
ByteDance’s AI Drug-Discovery Spinout Anew Labs Raises $290 Million at a $1.5 Billion Valuation
ByteDance has raised $290 million for Anew Labs, its AI drug-discovery spinout, at a $1.5 billion valuation in its first external funding round, with ByteDance retaining a 56% stake and…
Novo Signs Up to $1.4 Billion Drug-Discovery Deal With Orbis Medicines for Oral Cardiometabolic Drugs
Novo has signed a multi-target discovery and licensing deal with Orbis Medicines worth up to $1.4 billion, using AI-designed macrocycle molecules to develop oral cardiometabolic drugs, one day after its…
FDA Approves Ultragenyx’s Fayuvi, the First-Ever Treatment for Sanfilippo Syndrome Type A
The FDA has approved Fayuvi, a one-time AAV9 gene therapy from Ultragenyx, as the first-ever treatment for Sanfilippo syndrome Type A (MPS IIIA), a rare and fatal disease that progressively…
FDA Expands Bayer’s Kerendia Approval to Chronic Kidney Disease Associated With Type 1 Diabetes
The FDA has approved Bayer's Kerendia (finerenone) for chronic kidney disease associated with type 1 diabetes, the first new treatment for this patient group in over 30 years, based on…